Targeting exosomes enveloped <scp>EBV‐miR‐BART1‐5p‐antagomiRs</scp> for <scp>NPC</scp> therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis

Wang, Jianguo; Liu, Yan; Zhang, Yuanbin; Li, Xiaoyang; Fang, Min; Qian, Dong

doi:10.1002/cam4.5941

Cited by 6 publications

(2 citation statements)

References 52 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, inhibition of NF-κB significantly repressed exosome LMP1 secretion and limited NPC lung metastasis in nude mice. Other EBV-related exosomes include LMP2A [152], BART1 [153], HMGA2 [154]. These exosomes are found to promote tumor metastasis and modulate immunosuppressive TME.…”

Section: Exosomesmentioning

confidence: 99%

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Liu,

Tang,

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

The incidence of nasopharyngeal carcinoma (NPC) exhibits significant variations across different ethnic groups and geographical regions, with Southeast Asia and North Africa being endemic areas. Of note, Epstein-Barr virus (EBV) infection is closely associated with almost all of the undifferentiated NPC cases. Over the past three decades, radiation therapy and chemotherapy have formed the cornerstone of NPC treatment. However, recent advancements in immunotherapy have introduced a range of promising approaches for managing NPC. In light of these developments, it has become evident that a deeper understanding of the tumor microenvironment (TME) is crucial. The TME serves a dual function, acting as a promoter of tumorigenesis while also orchestrating immunosuppression, thereby facilitating cancer progression and enabling immune evasion. Consequently, a comprehensive comprehension of the TME and its intricate involvement in the initiation, progression, and metastasis of NPC is imperative for the development of effective anticancer drugs. Moreover, given the complexity of TME and the inter-patient heterogeneity, personalized treatment should be designed to maximize therapeutic efficacy and circumvent drug resistance. This review aims to provide an in-depth exploration of the TME within the context of EBV-induced NPC, with a particular emphasis on its pivotal role in regulating intercellular communication and shaping treatment responses. Additionally, the review offers a concise summary of drug resistance mechanisms and potential strategies for their reversal, specifically in relation to chemoradiation therapy, targeted therapy, and immunotherapy. Furthermore, recent advances in clinical trials pertaining to NPC are also discussed.

show abstract

Section: Exosomesmentioning

confidence: 99%

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Liu,

Tang,

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

show abstract

“… Dumontel 80 2022 Lymphatic cancer Freeze-thaw cycle ZnO Zinc oxide-loaded exosomes can specifically target lymphoma cells through surface modification with CD20. Wang 81 2023 Nasopharyngeal carcinoma Transfection EBV-miRNA-BART1-5p-antagonist miRNA-BART1-5p antagonist-loaded exosomes inhibit angiogenesis and induce cell apoptosis in tumor tissues. Cardiovascular diseases Gray 82 2015 Myocardial infarction Drug co-incubation miRNA Co-incubation of drugs and parental cells under hypoxic conditions increases angiogenic miRNA levels in exosomes, which induces angiogenesis.…”

Section: Clinical Application Of Drug-loaded Exosomesmentioning

confidence: 99%

Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications

Tian,

Han,

Song

et al. 2023

IJN

View full text Add to dashboard Cite

Exosomes are nano-sized membrane vesicles that transfer bioactive molecules between cells and modulate various biological processes under physiological and pathological conditions. By applying bioengineering technologies, exosomes can be modified to express specific markers or carry therapeutic cargo and emerge as novel platforms for the treatment of cancer, neurological, cardiovascular, immune, and infectious diseases. However, there are many challenges and uncertainties in the clinical translation of exosomes. This review aims to provide an overview of the recent advances and challenges in the translation of engineered exosomes, with a special focus on the methods and strategies for loading drugs into exosomes, the pros and cons of different loading methods, and the optimization of exosome production based on the drugs to be encapsulated. Moreover, we also summarize the current clinical applications and prospects of engineered exosomes, as well as the potential risks and limitations that need to be addressed in exosome engineering, including the standardization of exosome preparation and engineering protocols, the quality and quantity of exosomes, the control of drug release, and the immunogenicity and cytotoxicity of exosomes. Overall, engineered exosomes represent an exciting frontier in nanomedicine, but they still face challenges in large-scale production, the maintenance of storage stability, and clinical translation. With continuous advances in this field, exosome-based drug formulation could offer great promise for the targeted treatment of human diseases.

show abstract

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 6 publications

References 52 publications

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications

Targeting exosomes enveloped EBV‐miR‐BART1‐5p‐antagomiRs for NPC therapy through both anti‐vasculogenic mimicry and anti‐angiogenesis

Contact Info

Product

Resources

About